Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits

Angelique G. S. C. Jansen*, Gerwin D. Rodenburg, Sabine C. de Greeff, Eelko Hak, Reinier H. Veenhoven, Lodewijk Spanjaard, Leo M. Schouls, Elisabeth A. M. Sanders, Arie van der Ende

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    58 Citations (Scopus)

    Abstract

    With a retrospective study of invasive pneumococcal disease (IPD) surveillance data representative for similar to 25% of the Dutch population (1275 hospitalized cases) over the period June 2004-June 2006 prior to the implementation of the 7-valent pneumococcal conjugate vaccine (PCV7), the aim was to provide baseline data on IPD for the interpretation of changes after implementation of conjugate vaccines. The IPD incidence peaked in 3-5-mnth-olds (63 cases per 100,000 persons yearly) and increased in adulthood, particularly after the age of 60 yrs, from 26 cases in 60-64-yr-olds to 97 cases per 100,000 in persons >= 90 yrs. Beyond the age of 4 yrs, 19% of IPD patients were immunocompromised, and this considerable percentage may have implications for vaccine efficacy. (C) 2009 Elsevier Ltd. All rights reserved.

    Original languageEnglish
    Pages (from-to)2394-2401
    Number of pages8
    JournalVaccine
    Volume27
    Issue number17
    DOIs
    Publication statusPublished - 14-Apr-2009

    Keywords

    • Invasive pneumococcal disease
    • Epidemiology
    • Serotype distribution
    • Disease course
    • Outcome
    • 3-YEAR MULTICENTER SURVEILLANCE
    • CONJUGATE VACCINE
    • STREPTOCOCCUS-PNEUMONIAE
    • SEROTYPE DISTRIBUTION
    • UNITED-STATES
    • OLDER-ADULTS
    • CHILDREN
    • ERA
    • MENINGITIS
    • INFECTIONS

    Cite this